Abstract:Background While the past decades have seen an explosion of innovation in immunotherapies, most have failed in their clinical studies. One of the barriers encountered across these trials is that despite demonstrated cytoxicity, tumor immune evasion renders these treatments ineffective. Glioblastoma (GBM) is one of these tumors where experimental immunotherapeutics have continued to fail. The median survival of GBM remains at 15 months with the primary treatment being surgical resection, radiation, and chemotherapeutic over the past decade. To breach this stalemate, we require new therapeutics that both can target tumor immune evasion and can balance efficacy with toxicity. Our lab previously developed a subcutaneous autologous tumor vaccine utilizing a phagocytosis-stimulating ligand mannan anchored to irradiated (IR) tumor cells with the adjuvants toll-like receptor (TLR) agonists and immunostimulant anti-CD40 antibody (collectively abbreviated as MBTA). This regime allowed recognition of tumors resulting in a coordinated innate and adaptive immune response in both prophylactic and therapeutic studies with colon carcinoma, breast tumor, and GBM mouse models. The aim of our study was to generate a dendritic cell (DC) vaccine utilizing this strategy. Methods To assess if MBTA anchored GBM cells could mature DCs in-vitro, we harvested bone-marrow DCs (BMDCs) from mice and co-cultured them with MBTA GBM cells for 24 hours. Analysis was performed by flow cytometry and ELISA to confirm maturation markers and DC phenotype. To assess if MBTA DCs could protect against tumor metastasis, we utilized a melanoma (B16) prophylactic model by vaccinating mice 1 week before tail vein melanoma challenge. Results We found robust up-regulation of co-stimulatory molecules CD40, CD80 and CD86 and preferential upregulation of MHCI in the MBTA group with ELISA analysis demonstrating MBTA DCs significantly upregulated Type 1 cytokines (TNFa and IL-6) and limited regulatory cytokine (IL-10) secretion across GBM cell lines. Mice vaccinated with MBTA DCs had a significant decrease in lung metastasis compared to controls with lung immunohistochemistry demonstrating robust perivascular lymphocytic infiltration. Currently, we are working on demonstrating this efficacy in a glioblastoma model. Conclusions Collectively our results demonstrate that MBTA is an effective strategy to mature and load tumor antigens onto DCs ex-vivo. It has efficacy as a DC vaccine to prevent melanoma metastasis and potential as a glioblastoma DC vaccine. Acknowledgements The authors acknowledge the NCI-CCR affiliated staff for their assistance with animal housing and the NCI CCR Flow Cytometry Core Members for their expertise in flow cytometry Ethics Approval The National Cancer Institute (NCI) Animal Use and Care Committees approved the present study under NOB-010 and NOB-016.

Inhibitory effects of dendritic cell (DC) vaccine loading antigen with irradiated apoptotic MB49 tumor cells against bladder cancer cells in mice

Inhibitory Effects of a Dendritic Cell Vaccine Loaded with Radiation-Induced Apoptotic Tumor Cells on Tumor Cell Antigens in Mouse Bladder Cancer.

Dendritic cells pulsed with glioma RNA induce immunity against intracranial gliomas

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

Treatment of Intracranial G422 Glioblastoma with Bone Marrow-Derived Dendritic Cells Pulsed with Tumor Extracts

High-dose radiation-induced immunogenic cell death of bladder cancer cells leads to dendritic cell activation

Experimental Study of Treatment ofIntracranial G422 Glioblastoma with Bone Marrow-derived Dendritic Cells Vaccine

[Antitumor Immune Responses Induced by Idiotype-Pulsed Dendritic Cells with Cell-Penetrating Peptide Vaccination in Vivo].

Experimental study on the induction of cytotoxic T lymphocyte killing effects and dendritic-cell-based tumor vaccine prepared by high-intensity focused ultrasound

Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model

Dendritic Cells Loaded with Ultrasound-Ablated Tumour Induce in Vivo Specific Antitumour Immune Responses

Effect of tumor vaccine prepared by fusion of gastric cancer cells with dendritic cells

Dendritic Cells Pulsed with Heat-Treated U251 Cells Induce Antitumor Immunity Against Malignant Glioma

Reduction of Major Histocompatibility Complex Class I Expression on Bladder Carcinoma Following Tumor Antigen‐pulsed Dendritic Cell Vaccine: Implications for Immunoresistance in Therapy

Hypofractionated Radiation Induced the Immunogenic Death of Bladder Cancer Cells Leading to the Immune Sensitization of Dendritic Cells

Anti-bladder Cancer Effect in Vitro of Novel Dendritic Cell Vaccine Modified with B7-H1 Short Hairpin RNA and Pulsed with Tumor Antigen

Anti-gastric carcinoma efficacy of macrophage inflammation protein-1α recruited dendritic cell vaccine in mice

The anti-tumor immune response of specific cytotoxic T lymphocytes induced by breast cancer stem cells RNA-DCs vaccine

Anti-gastric carcinoma efficacy of gene modified dendritic cell vaccine recruited by macrophage inflammation protein-1

Effect of Treatment with Local Administration of Dendritic Cells Combination Radiotherapy on the Expression of Bcl-2 and Bax in Renal Tumor Bearing Mice